drugset / Trial / NCT03050398

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

NCT03050398

Phase 3 Terminated 8 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelOther

Summary

This study was a companion study to CLEE011A2404 which provided the opportunity for the collection of tumor tissue samples to better understand relevant mutations and the mechanisms responsible for resistance to treatment.

Timeline

Start
2017-06-07
Primary completion
2019-03-08
Completion
2019-03-08

Drugs

EvaluationDrugModalityDoseRoute
Background Letrozole Other / unclassified
Background Ribociclib Small molecule

Indications